Tectonic Therapeutic, Inc. (TECX) 10-Year Financial Performance & Capital Metrics

TECX • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutTectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.Show more

Revenue $0
EBITDA -$56M -30.6%
Net Income -$58M -35.4%
EPS (Diluted) -3.93 +65.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -206.56%
ROIC -
Debt/Equity 0.02
Interest Coverage -542.20 -84.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-25.84%

EPS CAGR

10Y-

5Y-

3Y-

TTM60.29%

ROCE

10Y Avg-124.19%

5Y Avg-96.12%

3Y Avg-138.36%

Latest-82.99%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	45K	380K	850K	1.21M	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-45K	-380K	-850K	-1.21M	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-7.44%	-1.24%	-0.42%	1%	-	-	-
Operating Expenses+	4.63M	18.34M	45.86M	74.96M	119.02M	15.61M	32.83M	44.65M	58.02M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-
Selling, General & Admin	1.96M	3.15M	10.77M	19.98M	32.99M	4.63M	7.18M	7.68M	16.65M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-
Research & Development	2.66M	15.19M	35.09M	54.97M	86.03M	10.98M	25.65M	36.97M	41.36M
R&D % of Revenue	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0
Operating Income+	-4.63M	-18.39M	-46.24M	-75.81M	-120.23M	-15.61M	-32.83M	-44.65M	-58.02M
Operating Margin %	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-2.98%	-1.52%	-0.64%	-0.59%	0.87%	-1.1%	-0.36%	-0.3%
EBITDA+	-4.66M	-18.34M	-45.86M	-74.96M	-119.02M	-15.25M	-31.82M	-43.17M	-56.37M
EBITDA Margin %	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-2.93%	-1.5%	-0.63%	-0.59%	0.87%	-1.09%	-0.36%	-0.31%
D&A (Non-Cash Add-back)	0	45K	380K	850K	1.21M	364K	1.01M	1.48M	1.65M
EBIT	-4.66M	-18.65M	-46.36M	-72.97M	-119.71M	-8.48M	-32.04M	-42.67M	-57.88M
Net Interest Income+	0	0	0	2.93M	719K	-224K	5K	429K	4.15M
Interest Income	6K	57K	1.73M	2.93M	719K	0	149K	581K	4.26M
Interest Expense	0	0	0	0	0	224K	144K	152K	107K
Other Income/Expense	-39K	-262K	-118K	2.84M	516K	6.68M	650K	1.82M	33K
Pretax Income+	-4.66M	-18.65M	-46.36M	-72.97M	-119.71M	-8.93M	-32.18M	-42.82M	-57.98M
Pretax Margin %	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-4.66M	-18.65M	-46.36M	-72.97M	-119.71M	-8.93M	-32.18M	-42.82M	-57.98M
Net Margin %	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-3%	-1.49%	-0.57%	-0.64%	0.93%	-2.6%	-0.33%	-0.35%
Net Income (Continuing)	-4.66M	-18.65M	-46.36M	-72.97M	-119.71M	-8.93M	-32.18M	-42.82M	-57.98M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.34	-9.35	-23.41	-31.92	-39.68	-33.36	-29.05	-11.53	-3.93
EPS Growth %	-	-3%	-1.5%	-0.36%	-0.24%	0.16%	0.13%	0.6%	0.66%
EPS (Basic)	-2.34	-9.35	-23.41	-31.92	-39.68	-33.36	-29.05	-11.59	-3.93
Diluted Shares Outstanding	1.99M	1.99M	1.98M	2.29M	3.02M	3.57M	3.64M	3.71M	14.77M
Basic Shares Outstanding	1.99M	1.99M	1.98M	2.29M	3.02M	3.57M	3.64M	3.69M	14.77M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.38M	6.31M	130.02M	195.7M	267.24M	28.62M	37.04M	30.88M	146.86M
Cash & Short-Term Investments	5.36M	5.96M	126.3M	187.04M	259.68M	28.06M	35.97M	28.77M	141.24M
Cash Only	5.36M	5.96M	126.3M	187.04M	259.68M	28.06M	35.97M	28.77M	141.24M
Short-Term Investments	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	1.54M	2.14M	2.56M	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	4K	60K	795K	620K	271K	557K	1.08M	2.12M	5.62M
Total Non-Current Assets+	24K	714K	3.46M	4.81M	3.99M	4.26M	10.17M	8.52M	6.05M
Property, Plant & Equipment	0	349K	2.63M	3.7M	3.06M	3.66M	9.55M	7.23M	5.3M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	24K	24K	492K	492K	492K	0	0	0	587K
Other Non-Current Assets	0	341K	333K	625K	436K	599K	613K	1.29M	156K
Total Assets+	5.4M	7.02M	133.48M	200.51M	271.23M	32.88M	47.21M	39.4M	152.91M
Asset Turnover	-	-	-	-	-	-	-	-	-
Asset Growth %	-	0.3%	18.01%	0.5%	0.35%	-0.88%	0.44%	-0.17%	2.88%
Total Current Liabilities+	891K	2.63M	10.61M	14.02M	16.61M	4.12M	7.84M	40.89M	11.61M
Accounts Payable	340K	527K	2.78M	3.95M	2.68M	1.81M	574K	409K	976K
Days Payables Outstanding	-	4.27K	2.67K	1.7K	811.04	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	177K	1.3M	5.21M	7.04M	7.53M	1.76M	2.66M	33.37M	3.58M
Current Ratio	6.03x	2.40x	12.26x	13.96x	16.09x	6.95x	4.73x	0.76x	12.65x
Quick Ratio	6.03x	2.40x	12.26x	13.96x	16.09x	6.95x	4.73x	0.76x	12.65x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	88K	1.03M	689K	484K	276K	43.72M	85.03M	83.15M	519K
Long-Term Debt	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	700K	4.34M	2.52M	519K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	88K	1.03M	689K	484K	276K	43.02M	80.68M	80.63M	0
Total Liabilities	979K	3.66M	11.29M	14.5M	16.89M	47.84M	92.86M	124.03M	12.13M
Total Debt+	0	0	0	0	0	1.05M	5.79M	4.34M	3.3M
Net Debt	-5.36M	-5.96M	-126.3M	-187.04M	-259.68M	-27.01M	-30.17M	-24.43M	-137.94M
Debt / Equity	-	-	-	-	-	-	-	-	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-69.69x	-227.99x	-293.74x	-542.20x
Total Equity+	4.42M	3.37M	122.18M	186.01M	254.34M	-14.96M	-45.65M	-84.64M	140.78M
Equity Growth %	-	-0.24%	35.31%	0.52%	0.37%	-1.06%	-2.05%	-0.85%	2.66%
Book Value per Share	2.22	1.69	61.68	81.37	84.30	-4.19	-12.53	-22.79	9.53
Total Shareholders' Equity	4.42M	3.37M	122.18M	186.01M	254.34M	-14.96M	-45.65M	-84.64M	140.78M
Common Stock	1K	1K	2K	3K	4K	0	0	0	2K
Retained Earnings	-4.83M	-23.48M	-71.74M	-144.7M	-264.42M	-15.6M	-47.78M	-90.6M	-148.59M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1K	-1K	0	0	0	0	0	-11K	9K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.31M	-16.38M	-37.65M	-67.67M	-98.8M	-12.45M	-97.21M	-40.68M	-59.08M
Operating CF Margin %	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-3.94%	-1.3%	-0.8%	-0.46%	0.87%	-6.81%	0.58%	-0.45%
Net Income	-4.66M	-18.65M	-46.36M	-72.97M	-119.71M	-8.93M	-32.18K	-42.82M	-57.98M
Depreciation & Amortization	0	45K	380K	850K	1.21M	364K	1.01K	1.48M	1.65M
Stock-Based Compensation	0	0	0	0	0	639K	1.12K	1.12M	3.49M
Deferred Taxes	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	463K	549K	2.9M	6.63M	15.46M	-6.45M	-89.78M	127K	4.04M
Working Capital Changes	710K	1.59M	4.18M	-2.18M	4.24M	1.92M	-7.4M	-584K	-10.28M
Change in Receivables	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	177K	176K	2.02M	1.03M	-881K	1.45M	-3.1M	-165K	-1.42M
Cash from Investing+	-24K	-383K	-1.83M	-1.58M	-1.18M	-2.12M	-267K	-279K	-156K
Capital Expenditures	0	-383K	-1.83M	-1.58M	-1.18M	-2.12M	-267K	-279K	-156K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0
Cash from Financing+	8.7M	17.37M	160.29M	129.99M	172.62M	41.42M	262K	33.75M	171.71M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	8.7M	-44K	0	0	0	2K	393K	121K	77.59M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.31M	-16.77M	-39.48M	-69.25M	-99.98M	-14.58M	-97.47M	-40.96M	-59.24M
FCF Margin %	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-4.06%	-1.35%	-0.75%	-0.44%	0.85%	-5.69%	0.58%	-0.45%
FCF per Share	-1.66	-8.40	-19.93	-30.29	-33.14	-4.08	-26.74	-11.03	-4.01
FCF Conversion (FCF/Net Income)	0.71x	0.88x	0.81x	0.93x	0.83x	1.40x	3.02x	0.95x	1.02x
Interest Paid	0	0	0	0	0	0	0	152K	107K
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-105.5%	-479.01%	-73.85%	-47.35%	-54.37%	-7.46%	-	-	-206.56%
Debt / Equity	-	-	-	-	-	-	-	-	0.02x
Interest Coverage	-	-	-	-	-	-69.69x	-227.99x	-293.74x	-542.20x
FCF Conversion	0.71x	0.88x	0.81x	0.93x	0.83x	1.40x	3.02x	0.95x	1.02x

Frequently Asked Questions

Growth & Financials

Tectonic Therapeutic, Inc. (TECX) grew revenue by 0.0% over the past year. Growth has been modest.

Tectonic Therapeutic, Inc. (TECX) reported a net loss of $67.3M for fiscal year 2024.

Dividend & Returns

Tectonic Therapeutic, Inc. (TECX) has a return on equity (ROE) of -206.6%. Negative ROE indicates the company is unprofitable.

Tectonic Therapeutic, Inc. (TECX) had negative free cash flow of $62.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Tectonic Therapeutic, Inc. (TECX) 10-Year Financial Performance & Capital Metrics

TECX • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $0
EBITDA -$56M -30.6%
Net Income -$58M -35.4%
EPS (Diluted) -3.93 +65.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -206.56%
ROIC -
Debt/Equity 0.02
Interest Coverage -542.20 -84.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-25.84%

EPS CAGR

10Y-

5Y-

3Y-

TTM60.29%

ROCE

10Y Avg-124.19%

5Y Avg-96.12%

3Y Avg-138.36%

Latest-82.99%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	45K	380K	850K	1.21M	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-45K	-380K	-850K	-1.21M	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-7.44%	-1.24%	-0.42%	1%	-	-	-
Operating Expenses+	4.63M	18.34M	45.86M	74.96M	119.02M	15.61M	32.83M	44.65M	58.02M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-
Selling, General & Admin	1.96M	3.15M	10.77M	19.98M	32.99M	4.63M	7.18M	7.68M	16.65M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-
Research & Development	2.66M	15.19M	35.09M	54.97M	86.03M	10.98M	25.65M	36.97M	41.36M
R&D % of Revenue	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0
Operating Income+	-4.63M	-18.39M	-46.24M	-75.81M	-120.23M	-15.61M	-32.83M	-44.65M	-58.02M
Operating Margin %	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-2.98%	-1.52%	-0.64%	-0.59%	0.87%	-1.1%	-0.36%	-0.3%
EBITDA+	-4.66M	-18.34M	-45.86M	-74.96M	-119.02M	-15.25M	-31.82M	-43.17M	-56.37M
EBITDA Margin %	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-2.93%	-1.5%	-0.63%	-0.59%	0.87%	-1.09%	-0.36%	-0.31%
D&A (Non-Cash Add-back)	0	45K	380K	850K	1.21M	364K	1.01M	1.48M	1.65M
EBIT	-4.66M	-18.65M	-46.36M	-72.97M	-119.71M	-8.48M	-32.04M	-42.67M	-57.88M
Net Interest Income+	0	0	0	2.93M	719K	-224K	5K	429K	4.15M
Interest Income	6K	57K	1.73M	2.93M	719K	0	149K	581K	4.26M
Interest Expense	0	0	0	0	0	224K	144K	152K	107K
Other Income/Expense	-39K	-262K	-118K	2.84M	516K	6.68M	650K	1.82M	33K
Pretax Income+	-4.66M	-18.65M	-46.36M	-72.97M	-119.71M	-8.93M	-32.18M	-42.82M	-57.98M
Pretax Margin %	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-4.66M	-18.65M	-46.36M	-72.97M	-119.71M	-8.93M	-32.18M	-42.82M	-57.98M
Net Margin %	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-3%	-1.49%	-0.57%	-0.64%	0.93%	-2.6%	-0.33%	-0.35%
Net Income (Continuing)	-4.66M	-18.65M	-46.36M	-72.97M	-119.71M	-8.93M	-32.18M	-42.82M	-57.98M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.34	-9.35	-23.41	-31.92	-39.68	-33.36	-29.05	-11.53	-3.93
EPS Growth %	-	-3%	-1.5%	-0.36%	-0.24%	0.16%	0.13%	0.6%	0.66%
EPS (Basic)	-2.34	-9.35	-23.41	-31.92	-39.68	-33.36	-29.05	-11.59	-3.93
Diluted Shares Outstanding	1.99M	1.99M	1.98M	2.29M	3.02M	3.57M	3.64M	3.71M	14.77M
Basic Shares Outstanding	1.99M	1.99M	1.98M	2.29M	3.02M	3.57M	3.64M	3.69M	14.77M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.38M	6.31M	130.02M	195.7M	267.24M	28.62M	37.04M	30.88M	146.86M
Cash & Short-Term Investments	5.36M	5.96M	126.3M	187.04M	259.68M	28.06M	35.97M	28.77M	141.24M
Cash Only	5.36M	5.96M	126.3M	187.04M	259.68M	28.06M	35.97M	28.77M	141.24M
Short-Term Investments	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	1.54M	2.14M	2.56M	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	4K	60K	795K	620K	271K	557K	1.08M	2.12M	5.62M
Total Non-Current Assets+	24K	714K	3.46M	4.81M	3.99M	4.26M	10.17M	8.52M	6.05M
Property, Plant & Equipment	0	349K	2.63M	3.7M	3.06M	3.66M	9.55M	7.23M	5.3M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	24K	24K	492K	492K	492K	0	0	0	587K
Other Non-Current Assets	0	341K	333K	625K	436K	599K	613K	1.29M	156K
Total Assets+	5.4M	7.02M	133.48M	200.51M	271.23M	32.88M	47.21M	39.4M	152.91M
Asset Turnover	-	-	-	-	-	-	-	-	-
Asset Growth %	-	0.3%	18.01%	0.5%	0.35%	-0.88%	0.44%	-0.17%	2.88%
Total Current Liabilities+	891K	2.63M	10.61M	14.02M	16.61M	4.12M	7.84M	40.89M	11.61M
Accounts Payable	340K	527K	2.78M	3.95M	2.68M	1.81M	574K	409K	976K
Days Payables Outstanding	-	4.27K	2.67K	1.7K	811.04	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	177K	1.3M	5.21M	7.04M	7.53M	1.76M	2.66M	33.37M	3.58M
Current Ratio	6.03x	2.40x	12.26x	13.96x	16.09x	6.95x	4.73x	0.76x	12.65x
Quick Ratio	6.03x	2.40x	12.26x	13.96x	16.09x	6.95x	4.73x	0.76x	12.65x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	88K	1.03M	689K	484K	276K	43.72M	85.03M	83.15M	519K
Long-Term Debt	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	700K	4.34M	2.52M	519K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	88K	1.03M	689K	484K	276K	43.02M	80.68M	80.63M	0
Total Liabilities	979K	3.66M	11.29M	14.5M	16.89M	47.84M	92.86M	124.03M	12.13M
Total Debt+	0	0	0	0	0	1.05M	5.79M	4.34M	3.3M
Net Debt	-5.36M	-5.96M	-126.3M	-187.04M	-259.68M	-27.01M	-30.17M	-24.43M	-137.94M
Debt / Equity	-	-	-	-	-	-	-	-	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-69.69x	-227.99x	-293.74x	-542.20x
Total Equity+	4.42M	3.37M	122.18M	186.01M	254.34M	-14.96M	-45.65M	-84.64M	140.78M
Equity Growth %	-	-0.24%	35.31%	0.52%	0.37%	-1.06%	-2.05%	-0.85%	2.66%
Book Value per Share	2.22	1.69	61.68	81.37	84.30	-4.19	-12.53	-22.79	9.53
Total Shareholders' Equity	4.42M	3.37M	122.18M	186.01M	254.34M	-14.96M	-45.65M	-84.64M	140.78M
Common Stock	1K	1K	2K	3K	4K	0	0	0	2K
Retained Earnings	-4.83M	-23.48M	-71.74M	-144.7M	-264.42M	-15.6M	-47.78M	-90.6M	-148.59M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1K	-1K	0	0	0	0	0	-11K	9K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.31M	-16.38M	-37.65M	-67.67M	-98.8M	-12.45M	-97.21M	-40.68M	-59.08M
Operating CF Margin %	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-3.94%	-1.3%	-0.8%	-0.46%	0.87%	-6.81%	0.58%	-0.45%
Net Income	-4.66M	-18.65M	-46.36M	-72.97M	-119.71M	-8.93M	-32.18K	-42.82M	-57.98M
Depreciation & Amortization	0	45K	380K	850K	1.21M	364K	1.01K	1.48M	1.65M
Stock-Based Compensation	0	0	0	0	0	639K	1.12K	1.12M	3.49M
Deferred Taxes	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	463K	549K	2.9M	6.63M	15.46M	-6.45M	-89.78M	127K	4.04M
Working Capital Changes	710K	1.59M	4.18M	-2.18M	4.24M	1.92M	-7.4M	-584K	-10.28M
Change in Receivables	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	177K	176K	2.02M	1.03M	-881K	1.45M	-3.1M	-165K	-1.42M
Cash from Investing+	-24K	-383K	-1.83M	-1.58M	-1.18M	-2.12M	-267K	-279K	-156K
Capital Expenditures	0	-383K	-1.83M	-1.58M	-1.18M	-2.12M	-267K	-279K	-156K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0
Cash from Financing+	8.7M	17.37M	160.29M	129.99M	172.62M	41.42M	262K	33.75M	171.71M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	8.7M	-44K	0	0	0	2K	393K	121K	77.59M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.31M	-16.77M	-39.48M	-69.25M	-99.98M	-14.58M	-97.47M	-40.96M	-59.24M
FCF Margin %	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-4.06%	-1.35%	-0.75%	-0.44%	0.85%	-5.69%	0.58%	-0.45%
FCF per Share	-1.66	-8.40	-19.93	-30.29	-33.14	-4.08	-26.74	-11.03	-4.01
FCF Conversion (FCF/Net Income)	0.71x	0.88x	0.81x	0.93x	0.83x	1.40x	3.02x	0.95x	1.02x
Interest Paid	0	0	0	0	0	0	0	152K	107K
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-105.5%	-479.01%	-73.85%	-47.35%	-54.37%	-7.46%	-	-	-206.56%
Debt / Equity	-	-	-	-	-	-	-	-	0.02x
Interest Coverage	-	-	-	-	-	-69.69x	-227.99x	-293.74x	-542.20x
FCF Conversion	0.71x	0.88x	0.81x	0.93x	0.83x	1.40x	3.02x	0.95x	1.02x

Frequently Asked Questions

Growth & Financials

Tectonic Therapeutic, Inc. (TECX) grew revenue by 0.0% over the past year. Growth has been modest.

Tectonic Therapeutic, Inc. (TECX) reported a net loss of $67.3M for fiscal year 2024.

Dividend & Returns

Tectonic Therapeutic, Inc. (TECX) has a return on equity (ROE) of -206.6%. Negative ROE indicates the company is unprofitable.

Tectonic Therapeutic, Inc. (TECX) had negative free cash flow of $62.7M in fiscal year 2024, likely due to heavy capital investments.